NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term. The closing is expected on or about May 18, 2026, subject to customary conditions.
This capital infusion is significant for NanoViricides as it continues to advance its clinical-stage, broad-spectrum antiviral drug NV-387. NV-387 has been granted Orphan Drug Designation by the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug is designed to target a wide range of respiratory viral illnesses, including influenza, RSV, coronaviruses, and others, and has shown effectiveness in lethal animal infection models for multiple viruses.
The offering underscores investor confidence in NanoViricides’ host-mimetic nanomedicine technology, which aims to create antivirals that viruses and their variants cannot escape. The proceeds will likely support further clinical development and manufacturing efforts for NV-387. For more details on the offering, view the full press release at https://ibn.fm/Z8Etj.
NanoViricides is a clinical-stage company and a leading global pioneer in broad-spectrum antivirals. Its technology platform mimics host cells to attract and neutralize viruses, potentially offering a first-line treatment for respiratory viral infections at the first doctor visit. The company’s newsroom provides ongoing updates at https://ibn.fm/NNVC.
This announcement is important as it provides NanoViricides with additional funding to advance NV-387 through clinical trials, bringing it closer to potential approval and commercialization. The Orphan Drug Designation further enhances the drug’s commercial prospects, offering incentives that could accelerate its path to market. The success of NV-387 could address significant unmet medical needs in treating respiratory viral illnesses, which pose ongoing public health challenges.
